Cost-Effectiveness of Novel Agent Regimens for Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients in India
Applied Health Economics and Health Policy · 2024-07 · 22 (4) · 569-582
DOI: 10.1007/s40258-024-00877-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Applied Health Economics and Health Policy, online erschienen am 07.03.2024. Verfasst von Jyoti Dixit und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Community Medicine and School of Public Health, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. Hauptthemen laut MEDLINE: Multiple Myeloma, Cost-Benefit Analysis, Hematopoietic Stem Cell Transplantation, Markov Chains. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: Department of Health Research, India.
Abstract (Originalsprache)
BACKGROUND: Survival outcomes for multiple myeloma have improved dramatically since the introduction of novel therapeutic agents. While these drugs are highly effective in improving survival outcomes and quality of life in patients with multiple myeloma, they come at a significant cost. We assessed the cost-effectiveness of bortezomib-based triplet or quadruplet drug regimens in isolation and followed by autologous hematopoietic stem cell transplantation (AHSCT) for the treatment of newly diagnosed multiple myeloma (NDMM) in the Indian context. METHODS: A Markov model was developed to assess the health and economic outcomes of novel drug regimens with and without AHSCT for the treatment of NDMM in India. We estimated the lifetime quality-adjusted life-years (QALYs) and costs in each scenario. The incremental cost-effectiveness ratios (ICERs) were computed and compared against the current willingness-to-pay threshold of a one-time per capita gross domestic product of ₹146,890 (US$1,927.70) for India. Parameter uncertainty was assessed through Monte Carlo probabilistic sensitivity analysis. RESULTS: Among seven treatment sequences, the VCd (bortezomib, cyclophosphamide, dexamethasone) alone arm has the lowest cost and health benefits as compared to four treatment sequences, namely VTd (bortezomib, thalidomide, dexamethasone) alone, VRd (bortezomib, lenalidomide, dexamethasone) alone, VRd plus AHSCT and DVRd (Daratumumab, bortezomib, lenalidomide, dexamethasone) plus AHSCT. It was found that VTd plus AHSCT and VCd plus AHSCT arms were extendedly dominated (ED) by combination of two alternative treatments. Among the five non-dominated strategies, VRd has a lowest incremental cost of ₹ 2,20,093 (US$2,888) per QALY gained compared to VTd alone followed by VRd plus AHSCT [₹3,14,530 (US$4,128) per QALY gained] in comparison to VRd alone. None of the novel treatment sequences were found to be cost-effective at the current WTP threshold of ₹1,46,890 (US$1,927.7). CONCLUSION: At the current WTP threshold of one-time per capita GDP (₹ 146,890) of India, VRd alone and VRd plus AHSCT has 38.1% and 6.9% probability to be cost-effective, respectively. Reduction in current reimbursement rates of novel drugs, namely VRd, lenalidomide, and pomalidomide plus dexamethasone under national insurance program and societal cost of transplant by 50%, would make VRd plus AHSCT and VTd plus AHSCT cost-effective at an incremental cost of ₹40,671 (US$34) and ₹97,639 (US$1,281) per QALY gained, respectively.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Community Medicine and School of Public Health, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
- Department of Clinical Haematology and Medical Oncology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. malhotrapankaj@hotmail.com.
- Department of Medical Oncology, Adyar Cancer Institute, Chennai, Tamil Nadu, India.
- Department of Medical Oncology, All India Institute of Medical Sciences (AIIMS), New Delhi, India.
- Department of Medical Oncology, Christian Medical College, Vellore, Tamil Nadu, India.
- Department of Radiation Oncology, Government Medical College and Hospital, Chandigarh, India.
ORCID-Profile: Shankar Prinja
Förderung
- Department of Health Research, India
Zitieren
APA
Dixit, J., Malhotra, P., Mehra, N., Mathew, A., Kumar, L., Singh, A., Gupta, N., Krishnamurthy, M. N., Roy, P. S., Kataki, A. C., Gupta, S., & Prinja, S. (2024). Cost-Effectiveness of Novel Agent Regimens for Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients in India. Applied Health Economics and Health Policy, 22(4), 569-582. https://doi.org/10.1007/s40258-024-00877-1
Vancouver
Dixit J, Malhotra P, Mehra N, Mathew A, Kumar L, Singh A, et al. Cost-Effectiveness of Novel Agent Regimens for Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients in India. Applied Health Economics and Health Policy. 2024;22(4):569-582. doi:10.1007/s40258-024-00877-1
BibTeX
@article{Dixit2024,
author = {Dixit, Jyoti and Malhotra, Pankaj and Mehra, Nikita and Mathew, Anisha and Kumar, Lalit and Singh, Ashish and Gupta, Nidhi and Krishnamurthy, Manjunath Nookala and Roy, Partha Sarathi and Kataki, Amal Chandra and Gupta, Sudeep and Prinja, Shankar},
title = {Cost-Effectiveness of Novel Agent Regimens for Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients in India},
journal = {Applied Health Economics and Health Policy},
year = {2024},
volume = {22},
number = {4},
pages = {569--582},
doi = {10.1007/s40258-024-00877-1}
}
EUVIMED